Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

This study tests whether adding a GLP-1 receptor agonist (a newer diabetes and weight-loss drug) to an existing combination of metformin and an SGLT-2 inhibitor can better control blood sugar in people with type 2 diabetes whose sugar levels remain too high on their current medications. **You may be eligible if...** - You are 18 to 75 years old with type 2 diabetes - Your BMI is 20 or above - You have been taking metformin (1000mg/day) plus an SGLT-2 inhibitor for at least 3 months - Your blood sugar (HbA1c) is still above 7.5% despite current treatment **You may NOT be eligible if...** - You have type 1 diabetes or other specific types of diabetes - You have severe kidney, liver, or heart disease - You have a history of pancreatitis or certain cancers (e.g., thyroid cancer) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.